The results indicated that FGF19 level was significantly increased in the HCC patients' serum (145.57 pg/ml ± 118.72) compared to non-HCC controls (90.18 pg/ml ± 13.88, p = 0.044 vs HCC). This evidence concerns the gene FGF19 and hepatocellular carcinoma.